# Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19

> **NCT04372628** · PHASE2 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 452 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Lopinavir/Ritonavir 400 mg/100 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04372628
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2021-12-16
- **Final completion:** 2022-01-18
- **Target enrollment:** 452 (ACTUAL)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04372628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04372628, "Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04372628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*